Citadel Advisors
NKTR icon

Citadel Advisors’s Nektar Therapeutics NKTR Stock Holding History

Citadel Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Sell
38,500
-49,500
-56% -$2.82M ﹤0.01% 5425
2025
Q4 		$3.72M Sell
88,000
-265,728
-75% -$14.9M ﹤0.01% 4786
2025
Q3 		$20.1M Buy
353,728
+68,152
+24% +$2.26M ﹤0.01% 2328
2025
Q2 		$7.38M Buy
285,576
+283,103
+11,448% +$3.18M ﹤0.01% 3473
2025
Q1 		$25.2K Buy
2,473
+2,146
+656% +$28K ﹤0.01% 12963
2024
Q4 		$4.56K Sell
327
-613
-65% -$10.8K ﹤0.01% 13922
2024
Q3 		$18.3K Sell
940
-300
-24% -$5.72K ﹤0.01% 12848
2024
Q2 		$23.1K Buy
1,240
+973
+364% +$20.5K ﹤0.01% 12507
2024
Q1 		$3.74K Sell
267
-40
-13% -$419 ﹤0.01% 13871
2023
Q4 		$2.6K Sell
307
-2,813
-90% -$21.3K ﹤0.01% 13680
2023
Q3 		$27.9K Sell
3,120
-173
-5% -$1.67K ﹤0.01% 12344
2023
Q2 		$28.4K Buy
3,293
+2,553
+345% +$27.2K ﹤0.01% 12412
2023
Q1 		$7.8K Buy
740
+100
+16% +$3.02K ﹤0.01% 13697
2022
Q4 		$21.7K Sell
640
-60
-9% -$2.9K ﹤0.01% 13082
2022
Q3 		$34K Sell
700
-2,093
-75% -$125K ﹤0.01% 11839
2022
Q2 		$159K Sell
2,793
-56,267
-95% -$3.55M ﹤0.01% 10930
2022
Q1 		$4.78M Buy
59,060
+50,920
+626% +$7.54M ﹤0.01% 4258
2021
Q4 		$1.65M Buy
8,140
+3,087
+61% +$670K ﹤0.01% 6674
2021
Q3 		$1.36M Sell
5,053
-4,414
-47% -$1.06M ﹤0.01% 7350
2021
Q2 		$2.44M Buy
9,467
+1,000
+12% +$277K ﹤0.01% 6108
2021
Q1 		$2.54M Buy
8,467
+2,054
+32% +$639K ﹤0.01% 5833
2020
Q4 		$1.64M Sell
6,413
-940
-13% -$243K ﹤0.01% 5800
2020
Q3 		$1.83M Sell
7,353
-1,734
-19% -$545K ﹤0.01% 4884
2020
Q2 		$3.16M Sell
9,087
-286
-3% -$89.2K ﹤0.01% 3769
2020
Q1 		$2.51M Sell
9,373
-5,800
-38% -$1.79M ﹤0.01% 3780
2019
Q4 		$4.91M Buy
15,173
+4,053
+36% +$1.18M ﹤0.01% 3100
2019
Q3 		$3.04M Buy
11,120
+2,327
+26% +$853K ﹤0.01% 3821
2019
Q2 		$4.69M Buy
8,793
+946
+12% +$474K ﹤0.01% 3179
2019
Q1 		$3.96M Sell
7,847
-4,073
-34% -$2.41M ﹤0.01% 3321
2018
Q4 		$5.88M Buy
11,920
+933
+8% +$563K ﹤0.01% 2561
2018
Q3 		$10M Sell
10,987
-3,766
-26% -$3.21M ﹤0.01% 2090
2018
Q2 		$10.8M Buy
14,753
+11,113
+305% +$12.8M 0.01% 1855
2018
Q1 		$5.8M Sell
3,640
-1,187
-25% -$1.53M ﹤0.01% 2306
2017
Q4 		$4.32M Buy
4,827
+4,194
+663% +$2.48M ﹤0.01% 2648
2017
Q3 		$228K Sell
633
-927
-59% -$290K ﹤0.01% 6496
2017
Q2 		$457K Sell
1,560
-260
-14% -$75.1K ﹤0.01% 5251
2017
Q1 		$641K Buy
1,820
+667
+58% +$150K ﹤0.01% 4651
2016
Q4 		$212K Buy
+1,153
New +$234K ﹤0.01% 6231
2016
Q1 		– Sell
-280
Closed -$71K – 7575
2015
Q4 		$71K Sell
280
-107
-28% -$22K ﹤0.01% 7018
2015
Q3 		$64K Sell
387
-120
-24% -$21.2K ﹤0.01% 7391
2015
Q2 		$95K Sell
507
-693
-58% -$119K ﹤0.01% 7124
2015
Q1 		$198K Buy
1,200
+607
+102% +$125K ﹤0.01% 6194
2014
Q4 		$138K Sell
593
-300
-34% -$64.1K ﹤0.01% 6361
2014
Q3 		$162K Sell
893
-314
-26% -$60.1K ﹤0.01% 5945
2014
Q2 		$232K Buy
1,207
+574
+91% +$102K ﹤0.01% 5395
2014
Q1 		$115K Buy
633
+320
+102% +$63.3K ﹤0.01% 6067
2013
Q4 		$53K Sell
313
-1,514
-83% -$244K ﹤0.01% 5998
2013
Q3 		$286K Buy
1,827
+1,187
+185% +$219K ﹤0.01% 4409
2013
Q2 		$111K Buy
+640
New +$98.2K ﹤0.01% 5142

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors's NKTR Position: Q1 2026 in Review

Citadel Advisors increased its Nektar Therapeutics (NKTR) stake by 66% in Q1 2026, buying an estimated $11.6M and bringing the position to 513,531 shares worth $36.9M. The position accounts for 0.01% of the portfolio, ranked #1649.

Citadel Advisors first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Citadel Advisors held 513,531 shares of Nektar Therapeutics worth $36.9M as of Q1 2026.
  • Citadel Advisors bought 203,754 Nektar Therapeutics shares in Q1 2026, an estimated $11.6M.
  • Nektar Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1649 holding.
  • Citadel Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.